Impact of Macular Edema on Visual Acuity in Uveitis

Lardenoye, Charlotte W. T. A.; Kooij, Bram van; Rothová, Aniki

doi:10.1016/j.ophtha.2006.03.027

Cited by 259 publications

(186 citation statements)

References 18 publications

Supporting

Mentioning

163

Contrasting

Unclassified

Order By: Relevance

“…1 Corticosteroids, administered through different ways, and anti-vascular endothelial growth factor (anti-VEGF), have long been used to treat ME due to non-infectious uveitis. 2,3 In addition, some studies advocate performing pars plana vitrectomy in patients with uveitic ME as a therapeutic procedure if more conservative measures failed.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis

Pelegrín

Maza

Molins

et al. 2015

Eye

View full text Add to dashboard Cite

Purpose To compare dexamethasone (DEX) intravitreal implant effect in nonvitrectomized (non-PPV) vs vitrectomized (PPV) eyes with macular edema (ME) secondary to non-infectious uveitis. Methods Medical records of patients with uveitic ME treated with DEX-intravitreal implant were reviewed. Main outcome measures were changes in central retinal thickness (CRT), best corrected visual acuity (BCVA), intraocular pressure (IOP), vitreous haze and adverse events. Statistical analysis was performed by Longitudinal Linear model using the General Estimating Equation methodology. Results Forty-two eyes of 32 patients were included. Median follow-up time was 18 months (interquartile range (IQR): 12-24). Median CRT showed its maximum decrease at the first month in non-PPV and PPV eyes without statistically significant differences between both groups (P = NS). Median Snellen BCVA, converted to logarithm (LogMAR), showed its maximum improvement at third month in both groups without statistically significant differences between them (P = NS). Median IOP was higher in non-PPV eyes than in PPV eyes from third (P = 0.025) to 12th month (P = 0.013). Vitreous haze score improved in both groups since first month and showed no differences (P = 0.706). Reinjection was performed in 45.2% of eyes at a median time of 5 months IQR: (5-6). Ocular hypertension (47.6%) was the most common adverse event.Conclusions DEX-intravitreal implant for uveitic ME has similar long-term safety profile and good response measured in terms of CRT decrease, BCVA, and vitreous haze improvement in both groups. Non-PPV eyes following DEX-intravitreal implant showed higher IOP increase than PPV eyes, showing the need for close IOP monitoring.

show abstract

Section: Introductionmentioning

confidence: 99%

“…7,8 Its effectiveness in the treatment of uveitic ME in PPV eyes has also been reported with good results. 9 1 The purpose of this study was to compare the effectiveness of 0.7-mg DEX-intravitreal implant in noninfectious uveitic ME in eyes without previous PPV (non-PPV) vs eyes with previous PPV.…”

Section: Introductionmentioning

confidence: 99%

Long-term evaluation of dexamethasone intravitreal implant in vitrectomized and non-vitrectomized eyes with macular edema secondary to non-infectious uveitis

Pelegrín

Maza

Molins

et al. 2015

Eye

View full text Add to dashboard Cite

show abstract

“…Cystoid macular edema is an accumulation of fluid in the most central part of the retina and is usually the main threat to vision in the ocular disorders mentioned above [13]. The pathological disruption of the retinal vessels in the macular area, i.e.…”

Section: Pathogenesis Of Cmementioning

confidence: 99%

Uveitis, diabetes, or cataracts? The mysterious case of the blurry left eye

Goldberg¹

2017

Eye Care Vis

View full text Add to dashboard Cite

Uveitis and diabetes can lead to macular edema and cataracts, resulting in reduced vision. This report discusses a unique case history of a patient presenting with all of these ocular pathologies, in which we were challenged to determine the cause of ocular inflammation and take a stepwise approach to managing each condition. Through utilization of clinical reasoning and ancillary testing, we were able to identify cataracts as the primary cause of reduced vision. The patient's chief complaint was successfully resolved with a treatment regimen of high-dosage topical steroid and cycloplegic agent.

show abstract

“…1,2 ME is the main condition associated with vision loss in uveitis, decreasing the visual acuity (VA) to o20/40 in about one-third of posterior uveitis patients. 3,4 Panuveitis and intermediate uveitis usually occur in conjunction with ME, with an incidence of 66% and 65%, respectively. 4 The most common known causes of Uveitis Macular Edema (UME) are HLA B27 positive anterior uveitis, juvenile idiopathic arthritis, intermediate uveitis due to sarcoidosis, multiple sclerosis, and pars-planitis, infections, posterior uveitis due to systemic diseases such as sarcoidosis, Behcet's disease, or due to intraocular dysimmunity such as Irvine Gass syndrome post-cataract surgery, Birdshot retinochoroidopathy (retinal vasculitis and depigmented choroiditis associated with HLA-A29), sympathic ophthalmia, and infectious retinitis.…”

Section: Introductionmentioning

confidence: 99%